Immutep (IMMP) Total Non-Current Liabilities (2011 - 2025)
Immutep (IMMP) posted Total Non-Current Liabilities of $847643.0 for Q4 2025, up 124.62% on a QoQ basis from $377360.5 in Q2 2025, and up 101.17% year-over-year from $421355.4 in Q4 2024.
Immutep (IMMP) Total Non-Current Liabilities (2011 - 2025) Analysis & Trends
Immutep's Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $847643.0 for Q4 2025.
- Quarterly Total Non-Current Liabilities rose 101.17% year-over-year to $847643.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $847643.0 (up 101.17% YoY) and the FY2025 annual result came in at $377360.5, down 63.56% from the prior year.
- Total Non-Current Liabilities was $847643.0 for Q4 2025 at Immutep, up from $377360.5 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.6 million in Q2 2021 and bottomed at $377360.5 in Q2 2025.
- A 5-year average of $1.2 million and a median of $941128.1 in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 75.64% — and 2025, when it jumped 101.17%.
- Immutep's Total Non-Current Liabilities stood at $2.5 million in 2021, then tumbled by 75.64% to $616473.7 in 2022, then jumped by 67.83% to $1.0 million in 2023, then slumped by 59.27% to $421355.4 in 2024, then soared by 101.17% to $847643.0 in 2025.
- Business Quant data shows IMMP's Total Non-Current Liabilities at $847643.0 in Q4 2025, $377360.5 in Q2 2025, and $421355.4 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Immutep | 569.08 Mn | 569.08 Mn | - | 847,642.96 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 847,642.96 |
| Jun 30, 2025 | 377,360.54 |
| Dec 31, 2024 | 421,355.35 |
| Jun 30, 2024 | 1.04 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Jun 30, 2023 | 807,041.90 |
| Dec 31, 2022 | 616,473.70 |
| Jun 30, 2022 | 1.20 Mn |
| Dec 31, 2021 | 2.53 Mn |
| Jun 30, 2021 | 2.63 Mn |
| Dec 31, 2020 | 7.72 Mn |
| Jun 30, 2020 | 6.51 Mn |
| Dec 31, 2019 | 7.49 Mn |
| Jun 30, 2019 | 7.60 Mn |
| Dec 31, 2018 | 7.59 Mn |
| Jun 30, 2018 | 7.29 Mn |
| Jun 30, 2017 | 4.36 Mn |
| Mar 31, 2017 | 4.27 Mn |
| Dec 31, 2016 | 23.45 Mn |
| Jun 30, 2016 | 4.30 Mn |